Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

CEO

Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.

Employees

Country

ISIN

US68386J2087

WKN

000A2QEW7

Listings

0 Comments

Share your thoughts

FAQ

What is Opthea Limited stock price today?▼

The current price of UKJ2.F is €3 EUR — it has increased by +2.04% in the past 24 hours. Watch Opthea Limited stock price performance more closely on the chart.

What is Opthea Limited stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Opthea Limited stocks are traded under the ticker UKJ2.F.

What is Opthea Limited market cap?▼

Today Opthea Limited has the market capitalization of 4.1B

What is Opthea Limited revenue for the last year?▼

Opthea Limited revenue for the last year amounts to 45,245.74 EUR.

What is Opthea Limited net income for the last year?▼

UKJ2.F net income for the last year is -291.76M EUR.

How many employees does Opthea Limited have?▼

As of April 09, 2026, the company has 33 employees.

In which sector is Opthea Limited located?▼

Opthea Limited operates in the Health Care sector.

When did Opthea Limited complete a stock split?▼

Opthea Limited has not had any recent stock splits.

Where is Opthea Limited headquartered?▼

Opthea Limited is headquartered in Melbourne, DE.